Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.36 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.36 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19856964 | 1.00 | GRM1 (0.40) | GRM1STAT6CYP51A1DRD2ALDH1A1 | |
| SCHEMBL19856967 | 0.86 | CCKBR (0.44) | STAT6CYP51A1DRD2HTRA1KDM4E | |
| SCHEMBL19856968 | 0.86 | CCKBR (0.44) | STAT6CYP51A1DRD2HTRA1KDM4E | |
| SCHEMBL7942248 | 0.84 | DRD2 (0.42) | STAT6CYP51A1DRD2ALDH1A1HTRA1 | |
| SCHEMBL19856885 | 0.84 | DRD2 (0.42) | STAT6CYP51A1DRD2ALDH1A1HTRA1 | |
| SCHEMBL19856900 | 0.84 | DRD2 (0.42) | STAT6CYP51A1DRD2ALDH1A1HTRA1 | |
| SCHEMBL19856886 | 0.84 | DRD2 (0.42) | STAT6CYP51A1DRD2ALDH1A1HTRA1 | |
| SCHEMBL19856884 | 0.84 | DRD2 (0.42) | STAT6CYP51A1DRD2ALDH1A1HTRA1 | |
| SCHEMBL1550055 | 0.81 | HRH4 (0.45) | STAT6CYP51A1DRD2HSPA5HSPA8 | |
| SCHEMBL1931303 | 0.80 | DRD2 (0.47) | STAT6CYP51A1DRD2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925857-B1 | USE OF TRPV4 ANTAGONISTS TO AMELIORATE HYDROCEPHALUS AND RELATED MATERIALS AND METHODS | UNIV INDIANA RES & TECH CORP (US) | 2018-02-14 | — | — | EP | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| JP-2011529082-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | GRM1 671/4885STAT6 2179/4885CYP51A1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.